Boehringer Ingelheim Lilly partner with DCRI to advance multidisciplinary care for people with type 2 diabetes & cardiovascular disease

Boehringer Ingelheim, Lilly partner with DCRI to advance multidisciplinary care for people with type 2 diabetes & cardiovascular disease

07:24 EST 15 Dec 2018 | PharmaBiz

The Duke Clinical Research Institute (DCRI), known for conducting ground breaking multinational clinical trial, managing major national patient registries, and performing landmark outcomes research

More From BioPortfolio on "Boehringer Ingelheim, Lilly partner with DCRI to advance multidisciplinary care for people with type 2 diabetes & cardiovascular disease"